CTOR
Citius Oncology Inc.

1,364
Mkt Cap
$94.45M
Volume
326,078.00
52W High
$6.19
52W Low
$0.5506
PE Ratio
-3.47
CTOR Fundamentals
Price
$1.02
Prev Close
$1.07
Open
$1.06
50D MA
$1.12
Beta
-2.47
Avg. Volume
148,956.72
EPS (Annual)
-$0.338
P/B
1.55
$148.61
Loading...
Loading...
News
all
press releases
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma Citius Oncology Announces...
PR Newswire·3d ago
News Placeholder
More News
News Placeholder
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update
Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) was the recipient of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling...
MarketBeat·5d ago
News Placeholder
Citius Oncology (NASDAQ:CTOR) Posts Earnings Results, Hits Estimates
Citius Oncology (NASDAQ:CTOR - Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of...
MarketBeat·22d ago
News Placeholder
Citius Oncology Q1 Earnings Summary & Key Takeaways
read more...
Benzinga·22d ago
News Placeholder
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of...
PR Newswire·22d ago
News Placeholder
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR PR Newswire...
PR Newswire·22d ago
News Placeholder
Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar
Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar Citius Oncology Expands International Distribution of LYMPHIR to European...
PR Newswire·24d ago
News Placeholder
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Up 22.3% in January
Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling...
MarketBeat·1mo ago
News Placeholder
Short Interest in Citius Oncology, Inc. (NASDAQ:CTOR) Expands By 51.2%
Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totaling 983,877 shares, a...
MarketBeat·2mo ago
News Placeholder
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of...
PR Newswire·2mo ago
<
1
2
...
>

Latest CTOR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.